Bacterial Vaginosis - Pipeline Review, H2 2018

  • ID: 4592413
  • Drug Pipelines
  • 62 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Evofem Biosciences Inc
  • Melinta Therapeutics Inc
  • Osel Inc
  • Pharmiva AB
  • Profarma
  • Starpharma Holdings Ltd
  • MORE
Bacterial Vaginosis - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Vaginosis - Pipeline Review, H2 2018, provides an overview of the Bacterial Vaginosis (Infectious Disease) pipeline landscape.

Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.

Report Highlights:

This latest pipeline guide Bacterial Vaginosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Bacterial Vaginosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Vaginosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Bacterial Vaginosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Bacterial Vaginosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bacterial Vaginosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bacterial Vaginosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Vaginosis (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bacterial Vaginosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bacterial Vaginosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Evofem Biosciences Inc
  • Melinta Therapeutics Inc
  • Osel Inc
  • Pharmiva AB
  • Profarma
  • Starpharma Holdings Ltd
  • MORE
Introduction

Report Coverage

Bacterial Vaginosis - Overview

Bacterial Vaginosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bacterial Vaginosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bacterial Vaginosis - Companies Involved in Therapeutics Development

Evofem Biosciences Inc

Melinta Therapeutics Inc

Osel Inc

Pharmiva AB

Profarma

Starpharma Holdings Ltd

Bacterial Vaginosis - Drug Profiles

Amphora - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

astodrimer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

clindamycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LACTIN-V - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metronidazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Bacterial Vaginosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

radezolid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

subtilosin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNP-2198 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOL-463 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bacterial Vaginosis - Dormant Projects

Bacterial Vaginosis - Discontinued Products

Bacterial Vaginosis - Product Development Milestones

Featured News & Press Releases

Apr 30, 2018: Starpharma completes US New Drug Application for VivaGel BV

Jan 18, 2018: Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis

Jan 17, 2018: Osel’s LACTIN-V Enters Clinical Study to Improve the Success Rate of IVF in Women With Imbalanced Vaginal Microbiomes

Nov 21, 2017: Starpharma: NDA submission for VivaGel BV in the US

Oct 25, 2017: VivaGel BV granted marketing approval in Australia

Aug 07, 2017: Successful VivaGel Phase 3 results and NDA planned for rBV

Jul 27, 2017: Evofem Biosciences Announces First Patient Enrolled in a Phase 3 Clinical Trial of AMPHORA for Prevention of Pregnancy

Jul 04, 2017: VivaGel BV phase 3 results timing and commercialisation

Jun 29, 2017: AMPHORA (L-lactic Acid, citric acid, and potassium bitartrate) Receives "Qualified Infectious Disease Product" (QIDP) Designation from the FDA

Mar 30, 2017: VivaGel BV phase 3 trials for prevention of BV completed

Jan 12, 2017: VivaGel BV granted QIDP and Fast Track designation by US FDA

Oct 13, 2016: Enrolment complete for Phase 3 VivaGel BV-R program

Aug 17, 2016: Evofem Announces First Patient Enrolled in a Clinical Trial to Determine the Effect and Duration of Amphora Gel on Vaginal pH

Jul 21, 2016: Osel Comments on New Study Showing Role of Vaginal Microbiome in Women Health

May 11, 2016: Osel Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Bacterial Vaginosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Bacterial Vaginosis - Pipeline by Evofem Biosciences Inc, H2 2018

Bacterial Vaginosis - Pipeline by Melinta Therapeutics Inc, H2 2018

Bacterial Vaginosis - Pipeline by Osel Inc, H2 2018

Bacterial Vaginosis - Pipeline by Pharmiva AB, H2 2018

Bacterial Vaginosis - Pipeline by Profarma, H2 2018

Bacterial Vaginosis - Pipeline by Starpharma Holdings Ltd, H2 2018

Bacterial Vaginosis - Dormant Projects, H2 2018

Bacterial Vaginosis - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Bacterial Vaginosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Evofem Biosciences Inc
  • Melinta Therapeutics Inc
  • Osel Inc
  • Pharmiva AB
  • Profarma
  • Starpharma Holdings Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll